| Effect of glucomannan on plasma lipid and glucose concentrations, body weight, and blood pressure: systematic review and meta-analysis. | |
| | |
MedLine Citation:
|
PMID: 18842808 Owner: NLM Status: MEDLINE |
Abstract/OtherAbstract:
|
BACKGROUND: Several clinical trials have investigated the impact of glucomannan on plasma lipids, body weight, fasting blood glucose (FBG), and blood pressure (BP), but have yielded conflicting results and had only modest sample sizes. OBJECTIVE: The objective was to perform a meta-analysis of randomized controlled trials of glucomannan to better characterize its impact on plasma lipids, FBG, body weight, and BP. DESIGN: A systematic literature search of MEDLINE, EMBASE, CINAHL, Web of Science, the Cochrane Library, and the Natural Medicines Comprehensive Database was conducted from the earliest possible date through November 2007. A random-effects model was used to calculate the weighted mean difference (WMD) and 95% CIs as the difference between the mean for the glucomannan and control groups. Standard methods for assessing statistical heterogeneity and publication bias were used. RESULTS: Fourteen studies (n = 531) met the inclusion criteria. The use of glucomannan significantly lowered total cholesterol [weighted mean difference (WMD): -19.28 mg/dL; 95% CI: -24.30, -14.26], LDL cholesterol (WMD: -15.99 mg/dL; 95% CI: -21.31, -10.67), triglycerides (WMD: -11.08 mg/dL; 95% CI: -22.07, -0.09), body weight (WMD: -0.79 kg; 95% CI: -1.53, -0.05), and FBG (WMD: -7.44 mg/dL; 95% CI: -14.16, -0.72). The use of glucomannan did not appear to significantly alter any other study endpoints. Pediatric patients, patients receiving dietary modification, and patients with impaired glucose metabolism did not benefit from glucomannan to the same degree. CONCLUSIONS: Glucomannan appears to beneficially affect total cholesterol, LDL cholesterol, triglycerides, body weight, and FBG, but not HDL cholesterol or BP. |
| | |
Authors:
|
Nitesh Sood; William L Baker; Craig I Coleman |
Related Documents
:
|
19716038 - High-density lipoprotein cholesterol levels and prognosis in advanced heart failure. 15168868 - Plasma lipid parameters in patients with alcoholic fatty liver after treatment with ess... 21291838 - Cholesterol, lipoproteins, and cognitive impairment. 8004358 - Polyenylphosphatidylcholine improves the lipoprotein profile in diabetic patients. 22621958 - Cardioprotective effects of metformin and vildagliptin in adult rats with insulin resis... 6612738 - An enhancing effect of the antihistaminic drug methapyrilene on rat liver carcinogenesi... |
Publication Detail:
|
Type: Journal Article; Meta-Analysis; Review |
Journal Detail:
|
Title: The American journal of clinical nutrition Volume: 88 ISSN: 1938-3207 ISO Abbreviation: Am. J. Clin. Nutr. Publication Date: 2008 Oct |
Date Detail:
|
Created Date: 2008-10-09 Completed Date: 2008-11-04 Revised Date: 2009-05-15 |
Medline Journal Info:
|
Nlm Unique ID: 0376027 Medline TA: Am J Clin Nutr Country: United States |
Other Details:
|
Languages: eng Pagination: 1167-75 Citation Subset: AIM; IM |
Affiliation:
|
University of Connecticut Schools of Medicine and Drug Information, Hartford Hospital, Hartford, CT 06102-5037, USA. |
Export Citation:
|
APA/MLA Format Download EndNote Download BibTex |
| MeSH Terms | |
Descriptor/Qualifier:
|
Blood Glucose
/
drug effects*,
metabolism Blood Pressure / drug effects*, physiology Body Weight / drug effects*, physiology Cholesterol / blood Fasting Humans Lipids / blood* Mannans / pharmacology* Randomized Controlled Trials as Topic Triglycerides / blood |
| Chemical | |
Reg. No./Substance:
|
0/Blood Glucose; 0/Lipids; 0/Mannans; 0/Triglycerides; 57-88-5/Cholesterol; 76081-94-2/(1-6)-alpha-glucomannan |
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine
Previous Document: Meta-analysis of the quantity of calcium excretion associated with the net acid excretion of the mod...
Next Document: The Wnt signaling regulator R-spondin 3 promotes angioblast and vascular development.